新型口服抗凝剂预防心房颤动患者卒中的临床评价
摘要
口服抗凝剂华法林在预防心房颤动（atrial fibrillation）致脑栓塞等疾病时虽疗效肯定，但是因其治疗窗狭窄，易受食物与药物干扰，服药期间需定期测定凝血酶原时间，所以使用相对比较复杂，患者依从性差。目前许多单位都在致力于研究开发新型口服抗凝剂，以获疗效大于或等于华法林而不良反应更少的药物。我们对最近新上市的口服抗凝剂在预防心房纤颤患者卒中时的应用进行综述。
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2013年第3期201-203,共3页
Chinese Journal of Neurology
参考文献16
-
1Blommel ML, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm, 2011, 68: 1506-1519.
-
2Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmaeother, 2010, 11 : 1403-1411.
-
3Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol, 2007,100 : 1419-1426.
-
4Fahas B. Prolongde and increased postoperative risk of venous thromboembolism : rationale for even more ' extended ' prophylaxia. Expert Rev Hematol, 2010,3 : 161-163.
-
5Paikin JS, Haroun MJ, Eikelboom JW. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY triM. Expert Rev Cardiovasc Ther, 2011, 9: 279-286.
-
6Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361 : 1139-1151.
-
7Garnock-Jones KP. Dabigatran etexilate : a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovase Drugs, 2011, 11 : 57-72.
-
8Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor X a inhibitor-are not affected by aspirin. J Clin Pharmacol, 2006, 46 : 981-990.
-
9Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365 : 883-891.
-
10Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011, 364: 806-817.
-
1余国膺.2006年全球心脏大会与欧洲年会心律失常最亮点[J].中国心脏起搏与心电生理杂志,2006,20(6):537-537.
-
2Palareti G.,Cosmi B.,Legnani C.,马超.以D-二聚体检测确定抗凝治疗持续时间[J].世界核心医学期刊文摘（心脏病学分册）,2007,0(4):4-5. 被引量：1
-
3喻慧.吸烟对2型糖尿病患者血脂的影响[J].大家健康（学术版）,2015(10):27-28.
-
4余虹,周伶霞.应用华法令治疗老年非瓣膜性心房颤动患者的护理体会[J].常州实用医学,2008,24(5):310-312. 被引量：3
-
5茜茜.超一半卒中伴心房颤动患者未接受抗凝治疗[J].中华医学信息导报,2014,0(24):9-9.
-
6孙同杰.小儿病毒性心肌炎26例临床分析[J].中国现代药物应用,2009,3(22):55-56. 被引量：1
-
7三大警示[J].中国健康月刊,2005(7).
-
8余国膺.口服抗凝剂、抗血小板治疗与外周动脉疾病关系[J].中国慢性病预防与控制,2007,15(5):468-468.
-
9丁宏岩,董强.口服抗凝剂应用近况[J].继续医学教育,2005,19(9):78-80.
-
10你问我答[J].中国社区医师,2013(38):42-42.
